News from ESMO: An AstraZeneca win in bladder cancer, and more

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.

AZ hits in bladder cancer, as regulatory issue looms

The applause mentioned above was for AstraZeneca’s Phase 3 NIAGARA study in bladder cancer, which showed that giving patients the checkpoint inhibitor Imfinzi — both before and after surgery — cut the risk of death by 25%. 

Read the rest…